Ekaterina S. Kropacheva

Ekaterina S. Kropacheva

Auto-generated profile, based on publicly available information

Ekaterina S. Kropacheva

Chazov National Medical Research Center of Cardiology

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2021 in Eurasian heart journal
Verified
Journal Article
Open access
PDF file
EPElizaveta Panchenko
Elizaveta Panchenko
TBTatyana Balakhonova
Tatyana Balakhonova
NDN. M. Danilov
N. M. Danilov
AKA. L. Komarov
A. L. Komarov
EKE. S. Kropachyova
E. S. Kropachyova
IYI. S. Yavelov
I. S. Yavelov
Disclaimer.The EAC Guidelines represent the views of the EAC, and were produced after careful consideration of the scientific and medical knowledge, and the evidence available at the time of their publication. The EAC is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the EAC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the EAC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strategies; however, the EAC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the EAC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.

28 October 2021 in Systemic Hypertension
Verified
Journal Article
Open access
PDF file
ICIrina E. Chazova
Irina E. Chazova
SGSergei P. Golitsyn
Sergei P. Golitsyn
JZJuliya V. Zhernakova
Juliya V. Zhernakova
EZEkaterina A. Zheleznova
Ekaterina A. Zheleznova
EKEkaterina S. Kropacheva
Ekaterina S. Kropacheva
ЮАЮричева Юлия Александровна
Юричева Юлия Александровна
Arterial hypertension (AH) is a leading risk factor for cardiovascular disease as well as it is the most common, independent and potentially reversible risk factor for atrial fibrillation (AF). AH contributes to the occurrence and maintenance of AF due to hemodynamic disorders, alterations in cardiomyocyte electrophysiological properties and structural remodeling in the atria. AF, which is also associated with an increased risk of cardiovascular events, is the most common arrhythmia. AH and AF often coexist, and their prevalence increases with age. This consensus provides the key features of the management of patients with these nosological units. The pathogenesis, risk stratification, and features of the selection of antihypertensive, antiarrhythmic and antithrombotic therapy are described in detail.

3 June 2020 in Kardiologiia
Verified
Journal Article
Open access
PDF file
YSYe. V. Shlyakhto
Ye. V. Shlyakhto
GAG. P. Arutyunov
G. P. Arutyunov
YBYu. N. Belenkov
Yu. N. Belenkov
ETE. I. Tarlovskaya
E. I. Tarlovskaya
AKA. O. Konradi
A. O. Konradi
VSV. A. Snezhitskiy
V. A. Snezhitskiy
This article discusses relevant aspects in the treatment of patients with COVID-19. Up-to-date information about principles for administration of statins, antithrombotics, and antiarrhythmics is presented. The authors addressed in detail specific features of reversing heart rhythm disorders in patients with coronavirus infection and the interaction of antiarrhythmic and antiviral drugs. Recommendations are provided for outpatient and inpatient antithrombotic therapy for patients with COVID-19. Issues of antithrombotic and antiviral drug interaction are discussed.

25 September 2025 in Eurasian heart journal
Verified
Journal Article
Open access
PDF file
SGS. P. Golitsyn
S. P. Golitsyn
EPElizaveta Panchenko
Elizaveta Panchenko
NMN. Yu. Mironov
N. Yu. Mironov
MBMaria Beliaeva
Maria Beliaeva
DGD. A. Gagloeva
D. A. Gagloeva
OSO. O. Shakhmatova
O. O. Shakhmatova
In this document we provide comprehensive review of contemporary approaches to diagnostic work-up and management of atrial fibrillation (AF) in adults. These guidelines are based on systematic methods to evaluate and classify evidence and provide a foundation for the delivery of quality cardiovascular care. Previous version of Eurasian clinical practice guidelines published in 2019 required revision due to a number of randomized clinical trials in major medical and surgical approaches to AF published in 2019-2024. Updated version of Eurasian Clinical practice guidelines based on methodology of European society of cardiology guidelines (2024) and American heart association/ American College of cardiology guidelines (2023). Revision included not only new scientific data but also took into consideration regional differences in healthcare systems, medical services and drugs availability and epidemiology of AF in Eurasian region.

15 September 2021 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
EKEkaterina S. Kropacheva
Ekaterina S. Kropacheva
MKMariia B. Khakimova
Mariia B. Khakimova
EKElena N. Krivosheeva
Elena N. Krivosheeva
OZOksana A. Zemlyanskaya
Oksana A. Zemlyanskaya
EPElizaveta Panchenko
Elizaveta Panchenko
ХБХакимова Мария Борисовна
Хакимова Мария Борисовна
Background. The rate of major bleeding in patients with atrial fibrillation receiving oral anticoagulants is 25% per year. Gastrointestinal bleedings are at least a half of major hemorrhagic complications. Currently, there is no optimal scale to calculate the risk of bleeding, and therefore the search for clinical predictors of gastrointestinal bleeding remains relevant. Aim. To assess the frequency and structure of large gastrointestinal bleeding, as well as to identify clinical predictors of their development based on long-term prospective observation of patients with atrial fibrillation receiving oral anticoagulants. Materials and methods. Data were obtained from single center prospective REGistry of long-term AnTithrombotic TherApy (REGATTA NCT043447187). Investigation based on a 20-year follow-up with 510 patients with atrial fibrillation with a high thromboembolic risk (median CHA2DS2-VASc was 4 points). The REGATTA registry assessed the frequency and structure of major gastrointestinal bleeding. Predictors of the development of 32 large gastrointestinal bleeding were identified based on the analysis of pairs with univariate and multivariate analyses. Results. The frequency of major gastrointestinal bleeding in patients with atrial fibrillation receiving oral anticoagulants at 1 year was 1.42 per 100 patients; the predominant localization was upper gastrointestinal tract. Predictors of the development of major gastrointestinal bleeding according to multiple regression data analysis were hemoglobin level 14.55 g/dL, body mass index 28.4 kg/m2, gastrointestinal ulcer or erosive lesion and major hemorrhagic complications in history of disease. In 1/2 cases the sourse of bleeding remained unclear. Conclusion. Searching for clinical predictors of gastrointestinal bleeding can identify patients receiving oral anticoagulants who is need of intensive monitoring risk factors to prevent the development of life-threatening bleeding and to provide with adequate anticoagulant therapy.

8 August 2021 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
EKE. N. Krivosheeva
E. N. Krivosheeva
EKE. S. Kropacheva
E. S. Kropacheva
АДА. Б. Добровольский
А. Б. Добровольский
ETE. V. Titaeva
E. V. Titaeva
EPElizaveta Panchenko
Elizaveta Panchenko
Aim. To study the predictive value of growth differentiation factor 15 (GDF-15) in patients with atrial fibrillation (AF) after elective percutaneous coronary intervention (PCI).Material and methods. The study included 150 patients (men, 69,3%) with AF receiving direct oral anticoagulants in combination with two (89,3%) or one antiplatelet agent (10,7%) after elective PCI. Median age was 71,0 [interquartile range, 66,0; 77,0] years. The median follow-up was 11,5 months [interquartile range, 8,0; 12,0]. The efficacy endpoint was the sum of cardiovascular events (CVEs), including cardiovascular death, ischemic stroke, venous thromboembolism, peripheral arterial thrombosis, acute coronary syndrome, and the need for emergency PCI. The safety endpoint was considered to be BARC type 2-5 bleeding. Prior to PCI, blood plasma samples were taken from patients to determine GDF-15 and D-dimer by enzyme immunoassay.Results. The incidence of CVEs was 16%. The incidence of BARC type 2-5 bleeding was 24,7%. The median GDF-15 level was 1270,0 pg/ml [953,0; 1778,0]. According to multiple regression, the GDF-15 level is associated with D-dimer (t=3,20; p=0,0018), diabetes (t=3,97; p=0,0001) and SYNTAX score II (t=4,77; p1191 pg/ml (p=0,0076) increases the likelihood of CVE (area under the curve, 0,647; confidence interval (CI), 0,5650,723). According to Kaplan-Meier survival curves, significant differences were found in terms of absence of CVEs during the follow-up period between the groups of patients with a GDF-15 >1191 and those with GDF-15 <1191 pg/ml (76% vs 94%, p=0,0032; relative risk, 4,36; CI 1,50-7,48). The relationship of GDF-15 level with BARC type 2-5 bleeding was not revealed.Conclusion. GDF-15 is a novel marker of CVE in AF patients after elective PCI.